A novel dual PI3Kα/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells

International Journal of Molecular Medicine

Volumn 24, Issue 1, 2009, Pages 97-101

  Zou, Zu Quan ^a   Zhang, Xiao Hong ^b   Wang, Feng ^c   Shen, Qi Jun ^b   Xu, Jin ^b   Zhang, Li Na ^b   Xing, Wen Hua ^b   Zhuo, Ren Jie ^b   Li, Duo ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b NINGBO UNIVERSITY   (China)

^c Clinical Laboratory   (China)

Author keywords

Cell cycle; Mammalian target of rapamycin; Non small cell lung cancer; PI 103; PI3K

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; CYCLIN D1; CYCLIN E; CYCLIN E1; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE ALPHA; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; PROTEIN P53; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; FURAN DERIVATIVE; GEFITINIB; PIK3CA PROTEIN, HUMAN; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; TUMOR SUPPRESSOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; UPREGULATION; CELL CYCLE; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; MUTATION; TUMOR CELL LINE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FURANS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MUTATION; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PYRIDINES; PYRIMIDINES; QUINAZOLINES; TUMOR SUPPRESSOR PROTEINS;

EID: 67649534502     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000212     Document Type: Article

References (32)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E and Thun MJ: Cancer statistics, 2003. CA Cancer J Clin 53: 5-26, 2003.
2. Janmaat ML, Kruyt FAE, Rodriguez JA and Giaccone G: Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 9: 2316-2326, 2003.
3. Haluska FG, Tsao H, Wu H, Haluska FS, Lazar A and Goel V: Genetic alterations in signaling pathways in melanoma. Clin Cancer Res 12: 2301-2307, 2006.
4. Nicholson KM and Anderson NG: The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 14: 381-395, 2002.
5. Engelman JA: The role of phosphoinositide 3-kinase pathway inhibitors in the treatment of lung cancer. Clin Cancer Res 13: 4637-4640, 2007.
6. Morrow CJ, Gray A and Dive C: Comparison of phosphatidylinositol-3-kinase signalling within a panel of human colorectal cancer cell lines with mutant or wild-type PIK3CA. FEBS Lett 579: 5123-5128, 2005.
7. Balsara BR, Pei J, Mitsuuchi Y, Page R, Klein-Szanto A, Wang H, Unger M and Testa JR: Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 25: 2053-2059, 2004.
8. Kim GE, Kim YB, Cho NH, Chung HC, Pyo HR, Lee JD, Park TK, Koom WS, Chun M and Suh CO: Synchronous coexpression of epidermal growth factor receptor and cyclo-oxygenase-2 in carcinomas of the uterine cervix: A potential predictor of poor survival. Clin Cancer Res 10: 1366-1374, 2004.
9. Chiang GG and Abraham RT: Targeting the mTOR signaling network in cancer. Trends Mol Med 13: 433-442, 2007.
10. Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H and Khuri FR: Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibitioned. Cancer Res 65: 7052-7058, 2005.
11. Fan QW, Cheng CK, Nicolaides TP, Hackett CS, Knight ZA, Shokat KM and Weiss WA: A dual phosphoinositide-3-kinase{alpha}/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res 67: 7960-7965, 2007.
12. Knight ZA, Gonzalez B, Feldman ME, Zunder ER, et al: A pharmacological map of the PI3-K family defines a role for p110[alpha] in insulin signaling. Cell 125: 733-747, 2006.
13. Kojima K, Shimanuki M, Shikamil M, et al: The dual PI3 kinaseα/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML. Leukemia 22: 1728-1736, 2008.
14. Park S, Chapuis N, Bardet V, et al: PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. Leukemia 22: 1698-1706, 2008.
15. Fan QW, Knight ZA, Goldenberg DD, Yu W, Mostov KE, Stokoe D, Shokat KM and Weiss WA: A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9: 341-349, 2006.
16. Janmaat ML, Rodriguez JA, Gallegos-Ruiz M, Kruyt FA and Giaccone G: Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. Int J Cancer 118: 209-214, 2006.
17. Whyte DB and Holbeck SL: Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines. Biochem and Biophys Res Commun 340: 469-475, 2006.
18. Sherr CJ and Roberts JM: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9: 1149-1163, 1995.
19. O'Reilly KE, Rojo F, She QB, et al: mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500-1508, 2006.
20. Wan X, Harkavy B, Shen N, Grohar P and Helman LJ: Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26: 1932-1940, 2006.
21. Jacks T and Weinberg RA: Cell-cycle control and its watchman. Nature 381: 643-644, 1996.
22. Shukla S and Gupta S: Molecular mechanisms for apigenin-induced cell-cycle arrest and apoptosis of hormone refractory human prostate carcinoma DU145 cells. Mol Carcinog 39: 114-126, 2004.
23. Singh RP, Agarwal C and Agarwal R: Inositol hexaphosphate inhibits growth, and induces G1 arrest and apoptotic death of prostate carcinoma DU145 cells: modulation of CDKI-CDK-cyclin and pRb-related protein-E2F complexes. Carcinogenesis 24: 555-563, 2003.
24. Li W, Sanki A, Karim R, Thompson J, Soon Lee C, Zhuang L, McCarthy S and Scolyer R: The role of cell cycle regulatory proteins in the pathogenesis of melanoma. Pathology 38: 287-301, 2006.
25. Galea CA, Wang Y, Sivakolundu SG and Kriwacki RW: Regulation of cell division by intrinsically unstructured proteins: intrinsic flexibility, modularity, and signaling conduits. Biochemistry 47: 7598-7609, 2008.
26. Liu G and Lozano G: p21 stability: Linking chaperones to a cell cycle checkpoint. Cancer Cell 7: 113-114, 2005.
27. Sharma SV, Gajowniczek P, Way IP, et al: A common signaling cascade may underlie 'addiction' to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 10: 425-435, 2006.
28. Buck E, Eyzaguirre A, Brown E, et al: Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther 5: 2676-2684, 2006.
29. Chun PY, Feng FY, Scheurer AM, Davis MA, Lawrence TS and Nyati MK: Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinomaed. Cancer Res 66: 981-988, 2006.
30. Nakamura H, Takamori S, Fujii T, Ono M, Yamana H, Kuwano M and Shirouzu K: Cooperative cell-growth inhibition by combination treatment with ZD1839 (Iressa) and trastuzumab (Herceptin) in non-small-cell lung cancer. Cancer Lett 230: 33-46, 2005.
31. Chen JS, Zhou LJ, Entin-Meer M, et al: Characterization of structurally distinct, isoform-selective phosphoinositide 3′-kinase inhibitors in combination with radiation in the treatment of glioblastoma. Mol Cancer Ther 7: 841-850, 2008.
32. Prevo R, Deutsch E, Sampson O, Diplexcito J, Cengel K, Harper J, O'Neill P, Mckenna WG, Patel S and Bernhard EJ: Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity. Cancer Res 68: 5915-5923, 2008.